Drug Trial Radar · NCT03479307
A Study Evaluating Bilastine Ophthalmic Solution 0.6% in the Conjunctival Allergen Challenge (Ora-CAC®) Model.
Last checked: Nov 19, 2026Latest source record: Mar 16, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
228
Actual
Start
Apr 7, 2018
Primary completion
Aug 9, 2018
Study completion Aug 10, 2018
Sponsor
- Lead sponsor
- Faes Farma, S.A.Industry
- Sponsor type
- Industry
- Collaborators
- ORA, Inc.
- First posted
- Mar 27, 2018
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
To evaluate the efficacy of Bilastine ophthalmic solution 0.6% compared to vehicle and Zaditen (Ketotifen ophthalmic solution 0.025%) for the treatment of the signs and symptoms of allergic conjunctivitis.
Conditions
- Allergic Conjunctivitis
Interventions
Bilastine Ophthalmic Solution 0.6%Drug
1 drop in each eye at 2 separate times during an 8 day period.
Ketotifen Ophthalmic Solution 0.025% (Zaditen)Drug
1 drop in each eye at 2 separate times during an 8 day period.
Vehicle of Bilastine Ophthalmic SolutionDrug
1 drop in each eye at 2 separate times during an 8 day period.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Ocular ItchingTime frame: The outcome measure was assessed at Visit 4b (Day 1: 16h post-treatment) and Visit 5 (Day 8 ±3, 15 minutes post-treatment).
Locations
6 sites in 1 country. Site status is shown where the registry gives one.
Cornea Consultants of AZ
Phoenix, Arizona
East West Eye Institute
Torrance, California
Andover Eye Associates
Andover, Massachusetts
Apex Eye
Mason, Ohio
Philadelphia Eye Associates
Philadelphia, Pennsylvania
Total Eye Care, P.A.
Memphis, Tennessee
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.